133 related articles for article (PubMed ID: 2467682)
1. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.
Hitchins RN; Newlands ES; Smith DB; Begent RH; Rustin GJ; Bagshawe KD
Br J Cancer; 1989 Feb; 59(2):236-42. PubMed ID: 2467682
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with poor prognosis anaplastic germ cell tumours (AGCT) of the testis and other sites.
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Crawford SM; Holden L
Int J Androl; 1987 Feb; 10(1):301-9. PubMed ID: 2438223
[TBL] [Abstract][Full Text] [Related]
3. Current optimum management of anaplastic germ cell tumours of the testis and other sites.
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Crawford SM; Holden L
Br J Urol; 1986 Jun; 58(3):307-14. PubMed ID: 2424538
[TBL] [Abstract][Full Text] [Related]
4. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
5. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
6. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity.
Husband DJ; Green JA
Eur J Cancer; 1992; 28(1):86-91. PubMed ID: 1373636
[TBL] [Abstract][Full Text] [Related]
7. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.
Bower M; Newlands ES; Holden L; Rustin GJ; Begent RH
Ann Oncol; 1997 May; 8(5):477-83. PubMed ID: 9233528
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime.
Cullen MH; Harper PG; Woodroffe CM; Kirkbride P; Clarke J
Br J Urol; 1988 Nov; 62(5):454-60. PubMed ID: 2463034
[TBL] [Abstract][Full Text] [Related]
9. The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy.
Crawford SM; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD
Br J Cancer; 1989 Feb; 59(2):243-6. PubMed ID: 2467683
[TBL] [Abstract][Full Text] [Related]
10. VP-16 in combinations for first-line treatment of malignant germ-cell tumors and gestational choriocarcinoma.
Newlands ES
Semin Oncol; 1985 Mar; 12(1 Suppl 2):37-41. PubMed ID: 2579442
[TBL] [Abstract][Full Text] [Related]
11. Tumour markers and POMB/ACE chemotherapy in the management of ovarian germ cell tumours (GCTs).
Newlands ES; Holden L; Bagshawe KD
Int J Biol Markers; 1988; 3(3):185-92. PubMed ID: 2466094
[TBL] [Abstract][Full Text] [Related]
12. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies.
Mann JR; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendszus KR
Cancer; 1989 May; 63(9):1657-67. PubMed ID: 2467734
[TBL] [Abstract][Full Text] [Related]
13. Successful management of metastatic and primary germ cell tumors in the brain.
Rustin GJ; Newlands ES; Bagshawe KD; Begent RH; Crawford SM
Cancer; 1986 Jun; 57(11):2108-13. PubMed ID: 2421864
[TBL] [Abstract][Full Text] [Related]
14. POMB/ACE chemotherapy for mediastinal germ cell tumours.
Bower M; Brock C; Holden L; Nelstrop A; Makey AR; Rustin GJ; Newlands ES
Eur J Cancer; 1997 May; 33(6):838-42. PubMed ID: 9291802
[TBL] [Abstract][Full Text] [Related]
15. Studies of the Australasian Germ Cell Trial Group: the management of advanced testis cancer.
Raghavan D; Levi J; Thomson D; Harvey V
Prog Clin Biol Res; 1990; 350():319-29. PubMed ID: 1696742
[No Abstract] [Full Text] [Related]
16. [Combination chemotherapy with POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) in advanced non-seminomatous testicular tumor].
Masuda F; Kawahara M; Asano K; Shirakawa H
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1847-50. PubMed ID: 7574821
[TBL] [Abstract][Full Text] [Related]
17. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.
Ledermann JA; Holden L; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD; Brampton M
Br J Urol; 1994 Aug; 74(2):225-30. PubMed ID: 7522874
[TBL] [Abstract][Full Text] [Related]
18. The UK Children's Cancer Study Group: testicular malignant germ cell tumours 1979-1988.
Huddart SN; Mann JR; Gornall P; Pearson D; Barrett A; Raafat F; Barnes JM; Wallendsus KR
J Pediatr Surg; 1990 Apr; 25(4):406-10. PubMed ID: 1691781
[TBL] [Abstract][Full Text] [Related]
19. POMB/ACE chemotherapy for mediastinal germ-cell tumours.
Droz JP
Eur J Cancer; 1997 May; 33(6):809-11. PubMed ID: 9291797
[No Abstract] [Full Text] [Related]
20. Fertility after chemotherapy for male and female germ cell tumours.
Rustin GJ; Pektasides D; Bagshawe KD; Newlands ES; Begent RH
Int J Androl; 1987 Feb; 10(1):389-92. PubMed ID: 2438231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
